Cough Variant Asthma
Conditions
Interventions
Group A:Inhalation Budesonide Formoterol Aerosol (pMDI): (100 µg/6 µg per inhalation), 2 inhalations each time, twice a day (once in the morning and once in the evening)
Group B:Budesonide Formoterol Powder for Inhalation (DPI): (160 µg/4.5 µg per inhalation), 2 inhalations per time, twice a day (once in the morning and once in the evening)
Sponsors
West China Hospital of Sichuan University - Department of Integrated Traditional Chinese and Western Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Age: 18 - 65 years old, gender not restricted 2. Meets the "CVA" diagnostic criteria 3. Cough occurred within 12 months (recent onset 40 mm 5. No structural lung disease manifestations on chest imaging (X-ray/CT) within the past 5 years (or since the onset of cough) 6. Baseline FEV1/FVC > 0.7 and FEV1 >= 80% predicted value 7. No systemic antitussive treatment before the initial diagnosis 8. Stable treatment of comorbidities (such as maintenance of basic disease medications for >= 4 weeks) 9. Voluntary signing of informed consent form and commitment to complete the entire follow-up process
Exclusion criteria
Exclusion criteria: 1. Patients with chronic cough of clear identifiable causes (such as eosinophilic bronchitis, gastroesophageal reflux cough, post-nasal drip syndrome, cough related to angiotensin-converting enzyme inhibitors (ACEI) drugs, etc.); 2. Patients with other respiratory system diseases that may affect the assessment (such as chronic obstructive pulmonary disease, bronchiectasis, interstitial lung disease, active tuberculosis, etc.); 3. Patients with severe systemic diseases (uncontrolled hypertension, heart failure, liver and kidney dysfunction, malignant tumors, etc.); 4. History of smoking; 5. Pregnant or lactating women; 6. Patients with mental disorders or cognitive dysfunction; 7. Individuals who have participated in other interventional clinical studies within the past 3 months.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Cough symptom score;Cough VAS score;Leicester Cough Questionnaire;Cough-specific Quality of Life Questionnaire;Lung function;Exhaled nitric oxide test; | — |
Secondary
| Measure | Time frame |
|---|---|
| Symptoms and changes in quality of life;The escalation and de-escalation of the ICS/LABA treatment regimen;Changes in small airway function; | — |
Countries
China
Contacts
Public ContactXin Zhang
West China Hospital of Sichuan University
Outcome results
None listed